Article Search

Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study

July 1, 2024

Mosunetuzumab has an impressive response rate and durability of response in heavily pre-treated patients with B-cell NHL. This was presented at our webinar on August 7, 2024 by the cellular therapy team, slides are available upon request. We have this drug available at select sites within our practice so please contact us if you have a patient in mind.

Read More »

Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia

July 1, 2024

Maybe it’s me, but I find these prognostic/risk stratification tools helpful especially when they are simple. This study shows that LDH, albumin, age of 66-75 all were strongly prognostic. This can be easily applied in the clinic to our patients when advising the risk of the disease and the need for potential therapy. Recall that there is a growing armamentarium of drugs in this disease, as well as clinical trials, within our practice.

Read More »

Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

September 1, 2022

Nice study from Emory quantifying the increased risk of infection in this vulnerable group.  These patients should remain vigilant in today’s environment and be considered for pre-exposure prophylaxis where available, in addition to staying up to date with vaccinations and follow-up boosters.   Even in untreated patients, titers were 11-fold lower than healthy vaccinees, confirming the disease causes an inherent immunodeficiency to COVID19.

Read More »

Keyword Search

  • Article Search

  • Cancer Types

  • Month Contributed

  • Show FCS Articles Only

  • Sort Order

  • Number of Posts

Menu

View Our Privacy Policy

About This Site

FCS Hematology Oncology Review creates a platform for our physician network to observe the most recent articles and studies available in the oncology and hematology world. By sharing these articles we are building our wealth of knowledge of new observations and treatments as they come available.

FCS logo
Facebook Linkedin Youtube Instagram Flickr